Outlook Therapeutics
OTLK
49 hedge funds and large institutions have $30.3M invested in Outlook Therapeutics in 2021 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 2 closing their positions.
950% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 2
291% more capital invested
Capital invested by funds: $7.76M → $30.3M (+$22.5M)
63% more funds holding
Funds holding: 30 → 49 (+19)
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
0.15% more ownership
Funds ownership: 0.23% → 0.39% (+0.15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.51M |
| 2 |
BlackRock
New York
|
+$3.34M |
| 3 |
Two Sigma Investments
New York
|
+$2.04M |
| 4 |
Renaissance Technologies
New York
|
+$1.49M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$906K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$188K |
| 2 |
VF
Virtu Financial
New York
|
-$179K |
| 3 |
Capstone Investment Advisors
New York
|
-$83.7K |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$35K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$30K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$30K | -1,169 | Closed |
|
OTLK Hedge Fund Activity: Q1 2021 in Review
49 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q1 2021, worth a combined $30.3M — up 291% from $7.76M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new OTLK positions and 2 closed out — a net gain of 19 holders — while 12 added to existing stakes and 8 trimmed.
The largest buyer was Vanguard Group, adding an estimated $3.51M. The largest seller was Jacobs Levy Equity Management, cutting an estimated $188K.
- 49 institutional investors held Outlook Therapeutics (OTLK) as of Q1 2021, up from 30 in Q4 2020.
- Funds reported $30.3M of Outlook Therapeutics stock for Q1 2021, up 291% quarter-over-quarter.
- 21 funds opened new Outlook Therapeutics positions in Q1 2021 and 2 closed out, a net change of +19 holders.
- The largest Outlook Therapeutics buyer in Q1 2021 was Vanguard Group, an estimated $3.51M added.
- The largest Outlook Therapeutics seller in Q1 2021 was Jacobs Levy Equity Management, an estimated $188K sold.
Based on aggregated 13F filings for Q1 2021.